Citius Oncology, Inc. CTOR Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $1.67M-57.7% | $3.94M— | —— | —— | —— | ||
| $328.88K-58.3% | $789.21K— | —— | —— | —— | ||
| $1.34M-57.6% | $3.15M— | —— | —— | —— | ||
| 80.3%+0.3pp | 80%— | —— | —— | —— | ||
| $1.08M+6.0% | $1.02M-5.4% | $1.08M+14.7% | $938.28K-70.1% | $3.14M+148% | ||
| $23.63M+726% | $2.86M+114% | $1.34M-28.9% | $1.88M-16.1% | $2.24M-32.5% | ||
| $29.95M+256% | $8.41M+78.4% | $4.71M-4.7% | $4.94M-33.8% | $7.47M+16.8% | ||
| -$28.61M-445% | -$5.25M-11.5% | -$4.71M+4.7% | -$4.94M+33.8% | -$7.47M-16.8% | ||
| -1,716.2%-1,583pp | -133.2%— | —— | —— | —— | ||
| $33.03K-27.9% | $45.84K-20.0% | $57.28K-64.4% | $160.76K— | —— | ||
| $1.77M+10,199% | -$17.55K+61.3% | -$45.41K0.0% | -$45.41K0.0% | -$45.41K0.0% | ||
| -$26.84M-409% | -$5.27M-11.4% | -$4.73M+7.3% | -$5.11M+31.7% | -$7.47M-16.8% | ||
| -$231.21K-188% | $264.24K0.0% | $264.24K0.0% | $264.24K0.0% | $264.24K0.0% | ||
| -$26.61M-381% | -$5.53M-10.8% | -$5M+7.0% | -$5.37M+30.6% | -$7.74M-16.2% | ||
| -1,596%-1,456pp | -140.3%— | —— | —— | —— | ||
| -$0.27-350% | -$0.060.0% | -$0.06+25.0% | -$0.08+27.3% | -$0.11-22.2% | ||
| -$28.61M-445% | -$5.25M-11.5% | -$4.71M+4.7% | -$4.94M+33.8% | -$7.47M-16.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Citius Oncology, Inc. profitable?
- Citius Oncology, Inc. is not currently profitable: it reported a net loss of $42.5M over the trailing twelve months.
- What is Citius Oncology, Inc.'s earnings per share?
- Citius Oncology, Inc.'s diluted EPS over the trailing twelve months is $-0.47.
- Where does Citius Oncology, Inc.'s income statement data come from?
- Every line is extracted from Citius Oncology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.